Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

Analysis of 209 studies shows what natural remedies seem to work, those that might work and why a lot more research is needed ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

This article explains why Latin Americas demographic diversity, cost profile, and accelerating digital health infrastructure ...

BeOne aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

High blood pressure, high blood sugar and elevated “bad” cholesterol (low-density lipoprotein or LDL cholesterol) are all ...

Key Points Net revenue (GAAP) dropped 18.1% year-over-year in Q2 2025, as reimbursement pressure continued to impact results despite increased unit sales for DEXTENZA. Research and development ...

Hepatocellular carcinoma remains a substantial global public health concern, disproportionately affecting low-income and middle-income countries, particularly in Africa.1 Its burden in Africa is ...

If Telix can crack a better therapy for key cancers in its remit, its $7 billion market valuation looks only the start, ...